Skip to main content

Market Overview

Aeterna Zentaris Starts Research Study On How Well Macimorelin Works For Growth Hormone Deficiency Diagnosis

Share:
Aeterna Zentaris Starts Research Study On How Well Macimorelin Works For Growth Hormone Deficiency Diagnosis
  • Aeterna Zentaris Inc (NASDAQ: AEZShas commenced its pivotal Phase 3 DETECT trial evaluating macimorelin as a diagnosis of childhood-onset growth hormone deficiency (CGHD).
  • The investigational new drug application multicenter, open-label trial will investigate the efficacy and safety of a single oral dose of 1.0 mg/kg macimorelin acetate as a growth hormone stimulation test (GHST) in pediatric patients with suspected GHD.
  • The macimorelin test will be compared to clonidine and an arginine test. Both are known standard stimulation tests.
  • The study is expected to enroll approximately 100 participants.
  • Patient enrollment on track to start this quarter, with trial completion expected in Q3 2022.
  • Under new terms and conditions of the license agreement revised in November 2020, Aeterna will coordinate the activities related to the development of macimorelin in CGHD through a joint steering committee with Novo Nordisk A/S (NYSE: NVO).
  • Price Action: AEZS shares are trading 2.91% higher at $0.91 during the premarket session on the last check Thursday.
 

Related Articles (AEZS + NVO)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech News Penny Stocks Health Care Contracts FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com